RJA
SPPI

Raymond James & Associates’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Raymond James & Associates’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-34,600
Closed -$281K – 2249
2014
Q2 		$281K Buy
+34,600
New +$263K ﹤0.01% 2066

Other funds holding SPPI

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Raymond James & Associates's SPPI Position: Q3 2014 in Review

Raymond James & Associates sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q3 2014, closing a stake of 34,600 shares — an estimated $281K sold.

Raymond James & Associates first reported a position in SPPI in Q2 2014 and held it in 1 quarter. The position peaked at $281K in Q2 2014. 127 funds tracked by Wall St. Rank hold SPPI as of Q3 2014.

  • Raymond James & Associates reported no remaining Spectrum Pharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • Raymond James & Associates sold 34,600 Spectrum Pharmaceuticals Inc shares in Q3 2014, an estimated $281K.
  • Raymond James & Associates first reported a position in Spectrum Pharmaceuticals Inc in Q2 2014 and held it in 1 quarter.
  • Raymond James & Associates's Spectrum Pharmaceuticals Inc position peaked at $281K in Q2 2014.
  • 127 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q3 2014.

Based on Raymond James & Associates's 13F filing for Q3 2014, filed 14 Nov 2014.